SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.54+0.9%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1032)4/29/2000 8:52:00 AM
From: nigel bates  Read Replies (1) of 52153
 
Just like the old days for the parasites too. Surprised it took them so long -

April 28, 2000--Notice is hereby given that a class action lawsuit was filed in the United States District Court for the District of Connecticut on behalf of all persons who purchased the stock of PE Corporation Celera Genomics Group (``Celera'' or the ``Company'') (NYSE: CRA - news) in a secondary offering (the ``Secondary Offering'') of Celera common stock conducted by PE Corporation on February 29, 2000.
The complaint charges Celera and certain of its officers and directors with violating Sections 11, 12(a)(2) and 15(a) of the Securities Act of 1933.
The complaint alleges that the registration statement and prospectus issued in conjunction with the Secondary Offering were materially false and misleading in that they failed to disclose that Celera had engaged in discussions with the Human Genome Project (an international research organization supported by the U.S. and U.K. governments, among others) concerning collaborating on completing the map of the human genome and that those discussions had terminated in December 1999 because the Human Genome Project was opposed to Celera's demands for five-year exclusive rights to the data.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext